Pioneering Biosimilar Access for Patients

Biosimilars are FDA-approved medicines that match their reference biologic in terms of efficacy, safety, and quality, can generate savings for patients, and:

- Enhance patient access to more affordable versions of biologic medicines
- Create sustainability for overburdened health systems by increasing savings and making room for innovation and new medicines
- Lower the cost of biologics by encouraging competition in the biologics market

As of June 2021, 29 biosimilars have been approved by the FDA.

Biosimilar medicines could deliver up to $183 billion in savings to payers and the US healthcare system over 5 years (2021-2025). With these savings, health systems could reallocate resources to improve patient care.

Patients who took certain biosimilars paid on average up to 45% less out-of-pocket than those who took the reference product.

US biosimilars savings totaled $4.5 billion over the last 10 years, with accelerated savings of $2.2 billion in 2019 alone.

As a result of increased biosimilar availability, an estimated 1.2 million additional US patients could gain access to the life-changing biologic medicines they need by 2025.

Large* US employers could save up to $1.4 billion a year and realize significant savings for their employees by promoting the use of biosimilars in employee-sponsored health plans.

Advocating for legislation and programs that support access to biosimilar medicines can help improve patient access and increase savings. The adoption of focused, common sense federal and state policies will ensure the sustainability of the biosimilar medicines market and that patients receive the medicines they need.

Learn more at www.us.sandoz.com/biosimilars.

---


SANDOZ
A Novartis Division

© 2021 Sandoz Inc.